Elorac

Elorac is a privately owned specialty pharmaceutical company dedicated to the development and commercialization of new products in dermatology, allergy, and oncology. The company markets dermatological products in the United States through its dedicated internal sales force. In addition to the newly acquired Heprotect compound, Elorac's development pipeline includes: Naloxone Lotion for the treatment of pruritus associated with cutaneous T-cell lymphoma, a product containing an orphan drug and granted Fast Track designation by the U.S. Food and Drug Administration (FDA); Cidoxepin, a highly potent histamine H1 receptor antagonist for the relief of chronic urticaria; and a once-weekly tablet for nodular cystic acne.